Compulsory Acquisition of Shares in Magseis Fairfield ASA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
Oslo, Norway (5 January 2023) - Reference is made to the stock exchange announcement made on 3 January 2023 regarding the final results of the mandatory cash offer (the "Offer") made by TGS ASA ("TGS") to acquire all shares in Magseis Fairfield ASA ("Magseis Fairfield") not already held by TGS. Following completion and settlement of the Offer, TGS has acquired and holds a total of 264,890,034 shares in Magseis Fairfield, equivalent to approximately 97.49% of the outstanding shares and voting rights in Magseis Fairfield.
The board of directors of TGS has resolved, effective from after close of trading on Oslo Børs today, 5 January 2023, to carry out a compulsory acquisition of all remaining shares in Magseis Fairfield not owned by TGS, pursuant to section 4-25 of the Norwegian Public Limited Liability Companies Act and section 6-22 of the Norwegian Securities Trading Act. As a consequence, TGS has assumed ownership to all shares in Magseis Fairfield. The offered redemption price in the compulsory acquisition is NOK 8.08 per share in Magseis Fairfield, equal to the offer price per share in the completed Offer. The aggregate redemption amount has been placed on a separate bank account in accordance with Section 4-25 of the Norwegian Public Limited Liability Companies Act.
Settlement of the offered redemption price will take place on or about 13 January 2023. A notice regarding the compulsory acquisition will be sent to all former shareholders subject to the compulsory acquisition whose addresses are known. In addition, the compulsory acquisition will be announced through the electronic notice service of the Norwegian Register of Business Enterprises (Norwegian: Brønnøysundregistrene).
Any objections to, or rejection of, the offered redemption price must be made at the latest by 23:59 (CET) on 6 March 2023. Former shareholders of Magseis Fairfield who do not object to, or reject, the offered redemption price within this deadline will be deemed to have accepted the offered redemption price.
As a consequence of the compulsory acquisition, TGS will pursue a delisting of Magseis Fairfield's shares from Oslo Børs. A separate stock exchange announcement will be published regarding such delisting.
ABG Sundal Collier ASA acts as financial advisor to TGS and receiving agent. Advokatfirmaet Schjødt AS acts as legal advisor to TGS. Arctic Securities AS acts as financial advisor and Advokatfirmaet Thommessen AS acts as legal advisor to Magseis Fairfield.
TGS: Sven Børre Larsen, CFO
Tel: +47 909 43 673
TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
It may be unlawful to distribute this announcement in certain jurisdictions. This announcement is not for distribution in Australia, Canada, the Hong Kong special administrative region of the People's Republic of China, Japan, South Africa, the United States or to any other jurisdiction where such distribution would be unlawful. The information in this announcement does not constitute an offer of securities for sale in any jurisdiction. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This announcement does not constitute an offer for sale of, or a solicitation of an offer to purchase or subscribe for, any securities in the United States.
Neither TGS, Magseis Fairfield nor any of their advisors and/or any of their affiliates or any of their respective directors, officers, employees, advisers, agents or any other person(s) accept any responsibility or liability whatsoever for, or make any representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information or opinions in this announcement (or whether any information has been omitted from this announcement) or any other information relating to the compulsory acquisition, the Offer, TGS or Magseis Fairfield.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:50:33 CET | Press release
PRESS RELEASE Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software Wolters Kluwer CCH Tagetik AI-based financial planning solution empowers finance professionals to make faster and better-informed decisions. New York – Dec. 8, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that it has been recognized as a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. Earlier this month, Wolters Kluwer also received recognition as a Leader in the Gartner Magic Quadrant for Financial Close and Consolidation Software. CCH Tagetik Budgeting, Planning and Forecasting software is Wolters Kluwer’s AI-based, enterprise-wide planning solution, which helps global companies facilitate strategic, financial, and operational planning, including supply chain, workforce, and capital expenses. The solution, which supports customers across vertical industries, is particula
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment8.12.2023 17:50:00 CET | Press release
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programme Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgery) Kadcyla® (trastuzumab emtansine) compared to Herceptin® (trastuzumab): at the 7-year landmark OS rates were 89.07% and 84.37
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation8.12.2023 17:45:00 CET | Press release
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authorities Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.1 The inavolisib combination reduced the risk of disease worsening or death (progression-free survival; PFS) by 57% compared to palbociclib and fulvestrant alone (15.0 months vs 7.3 months;
Innofactor Plc: Share Repurchase 8.12.20238.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 8.12.2023Innofactor Plc: Share Repurchase 8.12.2023In the Helsinki Stock ExchangeTrade date 8.12.2023Bourse trade BuyShare IFA1VAmount 4,400SharesAverage price/ share 1.1700EURTotal cost 5,148.00EURInnofactor Plc now holds a total of 580 029 sharesincluding the shares repurchased on 8.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 email@example.com Attachment Innofactor_8.12_trades
Azerion publishes bond prospectus and applies for admission to trading of its bonds on Nasdaq Stockholm8.12.2023 17:26:44 CET | Press release
Amsterdam, 8 December 2023 – Azerion Group N.V. (the “Company”) has, on 14 September 2023, following a bookbuilding process, successfully placed EUR 165 million of senior secured floating rate bonds under a framework of EUR 300 million to qualified institutional investors internationally (the "Bonds"). The Dutch Authority for the Financial Markets (Autoriteit Financiële Markten (the “AFM”)) has on 8 December 2023 approved the prospectus in relation to the admission to trading of the Bonds (the "Prospectus"). The approval of the Prospectus has been notified to the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The Prospectus will be available on the AFM’s website (https://www.afm.nl/en/sector/registers/meldingenregisters/goedgekeurde-prospectussen) and, together with a Swedish translation of the summary of the Prospectus, on the Company’s website (https://www.azerion.com/reports/). The Company will apply for listing of the Bonds on the Corporate Bond List of Nasdaq St